* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Origins of Pharmacogenomics
Genetic engineering wikipedia , lookup
Medical genetics wikipedia , lookup
Human–animal hybrid wikipedia , lookup
Designer baby wikipedia , lookup
Oncogenomics wikipedia , lookup
No-SCAR (Scarless Cas9 Assisted Recombineering) Genome Editing wikipedia , lookup
Genome (book) wikipedia , lookup
Pathogenomics wikipedia , lookup
Minimal genome wikipedia , lookup
Non-coding DNA wikipedia , lookup
History of genetic engineering wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Human genetic variation wikipedia , lookup
Public health genomics wikipedia , lookup
Whole genome sequencing wikipedia , lookup
Genomic library wikipedia , lookup
Human genome wikipedia , lookup
Genome editing wikipedia , lookup
Genome evolution wikipedia , lookup
Origins of Pharmacogenomics Archibald Garrod - 1902 • • In 1902 Garrod characterized the condition of alcaptonuria as one resulting from an absence of the enzyme homogentisate oxidase. Garrod recognized that the condition was transmitted as a single recessive Mendelian trait. Archibald Garrod - 1902 • While studying alcaptonuria in humans, Garrod advanced the hypothesis that genetically determined differences in biochemical processes could be the cause of adverse reactions after the ingestion of drugs. Enzyme defects?? • Garrod went on to suggest that enzymes were implicated in the detoxification of foreign substances and that such a mechanism might fail in persons lacking a specific detoxifying enzyme. Malaria - 1944 • primaquine African-American soldiers taking the drug primaquine for malaria showed primaquine-induced hemolysis at a rate that was significantly higher than in Caucasian soldiers. Tuberculosis- 1940’s • • Peripheral neuropathy occurred in some patients taking isoniazid but not others. Patients that exhibited the adverse effect were labeled “slow metabolizers”….. 1950’s - Succinylcholine • • A very small percent of the population experiences prolonged muscle paralysis following administration of the muscle relaxant succinylcholine. Kalow described differences in patients ability to metabolize the succinylcholine based on genetic variability in their plasma cholinesterase enzyme. 1956 – Primaquine Toxicity • Researchers identify a “genetic-link” between primaquine and unwanted hemolytic reactions Motulsky - 1957 • After reviewing data from the isoniazid and succinylcholine trials Motulsky proposed that the inheritance of acquired traits might explain the individual differences in efficacy and adverse reactions for these drugs. Vogel - 1959 • First proposed the term “pharmacogenetics” to describe the genetic-based differences in drug response that were being documented. Kalow - 1962 • Wrote the first monograph on “Pharmacogenetics” (W. Kalow, Pharmacogenetics, 1962, Saunders, Philadelphia) 1970’s London • Physicians at St. Mary’s hospital note that the severe hypotensive response of a volunteer to the effects of debrisoquine was due to impaired oxidative metabolism in that subject. Identical Twins - 1970 • In the 1970’s Vesell showed that identical twins were more similar than fraternal twins with regards to the plasma half-life of numerous drugs. Implication was that multiple genes may determine individual drug metabolism….. Advent of Molecular Biology • Like most of science and medicine, the young field of pharmacogenetics benefited greatly from the advent of molecular biology techniques in the 80’s & 90’s. Molecular Biology • In the 1990’s simple PCR-based DNA tests became available for debrisoquine and acetylation polymorphism. Definition • Polymorphism - are changes in the genetic code (like mutations) that occur commonly enough in the population such that they are considered a variation on normal. These may be harmful, helpful or neither to the persons who have a polymorphism. The Human Genome Project 1990 • The ongoing effort to characterize and decode the human genome has likewise contributed greatly to the progress made in pharmacogenetics. The Human Genome Project • New technologies that arose from the Human genome Project such as DNA microarrays and lab card or “lab-on-a-chip” devices may eventually make it possible to cheaply and quickly prescreen patients for certain polymorphisms before drug therapy is initiated TPMT Deficiency - 1997 • Polymerase chain reaction used to detect thiopurine S-methyl transferase deficiency – a cause of dangerous complications arising from mercaptopurine & azathioprine therapy. SNP Consortium - 1999 • • A collaboration of various companied and institutions set up to discover the extent of single nucleotide polymorphisms (SNP’S) in the human genome. The original goal was to identify 300,000 but the final results identified 1.4 million! Draft Human Genome - 2000 • Human Genome Project leaders announce the completion of a draft sequence of the human genome Complete Human Genome 2003 • Human genome project is officially completed. FDA and Pharmacogenomics 2005 • FDA issue guidance to the pharmaceutical industry for pharmacogenomic data submission. Warfarin - 2007 • the FDA announced that warfarin’s label will carry new information describing the role of genetics in dosing. Table of Valid Genomic Biomarkers - 2008 • FDA releases a table listing genomic biomarkers that have established roles in determining drug response